Oramed Pharmaceuticals Inc. (ORMP) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Oramed Pharmaceuticals Inc. has evolved into a strategic operator of medical technology businesses, focusing on acquiring controlling interests in portfolio companies rather than solely holding securities. The quarter was defined by the closing of a major strategic transaction with Lifeward Ltd. and significant appreciation in the company's investment portfolio, particularly in Alpha Tau Medical Ltd.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenues | $0 | $2,000 |
| Operating Loss | $(3,659) | $(4,500) |
| Net Income (Loss) | $38,310 | $(7,642) |
| Diluted EPS | $0.91 | $(0.19) |
| Cash and Cash Equivalents | $13,202 | $74,516 |
| Total Assets | $268,847 | $139,894 |
| Working Capital Surplus | $58,587 | $114,185 |
Note: Q1 2025 cash balance shown is end-of-period; Q1 2026 cash decreased significantly due to dividend payments and investment activities.
Material Changes vs. Prior Period
- Profitability Shift: The company reported a net income of $38.3 million in Q1 2026, a reversal from a net loss of $7.6 million in Q1 2025. This was driven primarily by a $44.8 million gain in "Financial income (loss), net," largely due to the revaluation of investments in Alpha Tau ($36.4 million gain), Scilex, and Hapisga.
- Operating Expenses: Operating loss narrowed by 19% to $3.7 million. Research and Development (R&D) expenses decreased 28% to $1.6 million, and General and Administrative (G&A) expenses decreased 10% to $2.1 million.
- Revenue Recognition: Revenue was $0 in Q1 2026 compared to $2.0 million in Q1 2025. The prior period revenue was related to the Medicox License Agreement, which was recognized as "Other income" in Q1 2026 ($2.0 million) after the agreement was deemed no longer commercially viable following the Lifeward transaction.
- Dividend Payment: The company paid approximately $10.4 million in dividends during the quarter, significantly impacting cash flow from financing activities.
Guidance, Outlook, and Strategic Transactions
Lifeward Transaction (Closed March 25, 2026): Oramed transferred its POD™ (Protein Oral Delivery) technology platform and related assets to OraTech Ltd., which was acquired by Lifeward Ltd. In consideration, Oramed received:
- 1,250,363 Lifeward ordinary shares (approx. 45% ownership).
- Pre-funded warrants and share purchase warrants.
- A 4% revenue share on Lifeward's ReWalk products for up to 10 years.
- A $9.0 million senior secured convertible note (Initial Note) and associated warrants.
Alpha Tau Investment: Oramed holds a ~17% stake in Alpha Tau Medical Ltd. The fair value of this investment increased to $102.3 million (from $71.6 million at year-end 2025), contributing significantly to the quarter's net income. Alpha Tau received regulatory approval in Japan for its Alpha DaRT platform and is advancing pivotal trials in the U.S.
Liquidity and Outlook: Management believes current cash resources ($13.2 million) and short-term deposits ($11.1 million) are sufficient to fund planned activities for at least the next 12 months. However, the company notes that additional financing may be required in the future, which may not be available on acceptable terms.
Risks and Contingencies:
- Investment Volatility: A significant portion of assets and income is derived from fair value changes in investments (Alpha Tau, Scilex, Lifeward), which are subject to market fluctuations.
- Real Estate Loans: The company holds significant loans to real estate projects (e.g., Hapisga, Profit Sharing Loan Agreement) valued at fair value, exposing the company to market and execution risks.
- Geopolitical Risk: Operations in Israel remain subject to regional conflict risks, though management states there is no immediate risk to operations as of May 2026.
Investor Verification Checklist
- Investment Valuation: Verify the fair value assumptions and discount rates used for the Alpha Tau, Scilex, and Lifeward investments, as these drove the majority of the reported net income.
- Lifeward Note Terms: Review the conditions for the "Additional Notes" tranche ($9.0 million) which Oramed may be required to fund if Lifeward achieves specific sales or stock price milestones.
- Cash Burn vs. Income: Note the discrepancy between the reported net income ($38.3M) and the negative operating cash flow ($2.9M) and significant cash outflow from investing ($19.5M) and financing ($10.4M) activities.
- Dividend Sustainability: Assess the sustainability of the $0.25/share dividend paid in Q1 given the reduction in cash reserves and the shift to an investment-holding model.
- Real Estate Exposure: Confirm the status and collateral value of the Hapisga and other real estate loans, which represent a significant portion of long-term assets.